Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasm, Residual 1Multiple Myeloma 1Giant Cell Tumor of Bone 1Disease Progression 1Colorectal Neoplasms 1

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2durvalumab 2Nivolumab 2Gemcitabine 2Doxorubicin 2Dexamethasone 2tremelimumab 1tivozanib 1ricolinostat 1pomalidomide 1nilotinib 1capivasertib 1Zoledronic Acid 1Vitamin D 1Taxes 1Oxaliplatin 1Leucovorin 1Lenalidomide 1Fulvestrant 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cisplatin 1Calcium 1Bortezomib 1AZD 6244 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Disease Progression × Calcium × Clear all
NCT00171925 2012-04-11

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Novartis

Phase 3 Terminated
143 enrolled 10 charts
Plasma cell

Multiple Myeloma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡